Slide 1: Corporate Presentation: Powering the Bioindustrial Revolution with Better DNA
Exhibit 99.1 Powering Corporate May 2015the Presentation Bioindustrial Revolution with Better DNA™
Slide 2: Forward-Looking Statements and Safe Harbor
Forward-Looking Safe Some Reform development risks (i) anticipated position; ability, joint expenses, other 10-K, date Non-GAAP This Commission believes additional © performance. any to such 2upon ©2015 an Intrexon’s securities 2015 of Harbor presentation information. venture; and exemption distribu
Slide 3: Intrexon Corporate Profile
Intrexon Leader Founded Publicly 579 Mission: Core World Senior 3*Business Count © employees* 2015 technology: class team: inas traded Profile 1998 Industrial Model: Intrexon synthetic ofboard RJ 4/15/2015 (NYSE: Kirk, Exclusive UltraVecto Corp. engineer biology CEO; XON) AllChannel Krish rights Kri
Slide 4: Synthetic Biology Driving the Bio-Based Economy
Synthetic The Biology precise and Informatics Rational to… of providing instructions powerful To processes… Therapeutics, Health Fuels, Energy Biologics Bioremediation, Environment Lubricants Agriculture, Food Textiles, 4Consumer ©novel create robust 2015 combination Chemicals, Engineering, knowledg
Slide 5: Understanding the Code of DNA
Understanding Since 5genetic © 2015 itscode inception Intrexon and Intrexon’s Corp. Designing All rights understanding DNAreserved. Code of DNA’s modular nature has provided the foundation for its proprietary approach in the design and construction of complex gene programs utilizing the building blo
Slide 6: Intrexon's Expertise Across Multiple Host Platforms
Expertise Intrexon’s Human Bacterial Fungal Eukaryote Higher Algae Systems 6Microbial © 2015 Platform Plant Animal Human Fungal Across Intrexon Bacterial Animal expertise Platform Platform Plant Platform Platform Multiple Platform Corp. Platform is inHost DNA All Host Deterministic engineering right
Slide 7: Positioned to Capitalize on SynBio Products and Solutions
Well Synthetic Genetic Recombinase Animal Bacterial DNA Products MODs Algae Fungal Fuels CAR-T Aquaculture Gene Livestock Chemicals APIs Biologics Biopesticides Consumer 7Agriculture © 2015 Positioned Therapy Switches Code Cell Cellular Human and Intrexon Biology Therapy Products Solutions Plant Pro
Slide 8: Engineering Cellular Platforms
Engineering Cellular Human Intrexon T Before After Armed Increased Re-engineered 8Optimized © Cells 2015 Intrexon Non-targeted to Arabidopsis Plant Platforms Selected Intrexon target tolerance cell ofBacterial Bioengineering cell lines Biology—Illustrative cancer Host Corp. pathways to Methanotroph
Slide 9: Integrated Intrexon Technology Suite
Integrated UltraVector® gene modulate for LEAP® 9Intrexon ©genomic 2015 expression Cell has RNA Intrexon Technology modification built, Processing ispersistence aAttSite® modular, acquired Corp.Suite provides All Recombinases and object-oriented and rights translation integrated imaging reserved. en
Slide 10: UltraVector Platform: Design-Build-Test-Learn
Power Design Learn Software-driven Iterative Provides 10 © 2015 Test of Build design-build-test-learn™ rapid, the Intrexon UltraVector® scalable operating Corp. manufacturing All system Platform rights for process reserved. DNA assembly enables designline optimal andtofabrication construct designssi
Slide 11: Intrexon's Proprietary Database
Proprietary Intrexon’s Database Quantitative Data Intrexon Predictive Improvement 11 © mining, 2015 Approach Inventory ability proprietary Intrexon Database Expression modeling, Sampling removes Corp. Enabling database % and All time, Samples statistical rights Predictable maintains costScreened res
Slide 12: Controlling Gene Expression with RheoSwitch
Controlling RheoSwitch RheoSwitch® Transcriptional Modulates Provides Dose-dependent Clinically Allows 12 © 2015 for spatial validated protein Intrexon independent Gene Therapeutic gene control and gene Expression expression regulation with Corp. temporal expression of regulation excellent System aA
Slide 13: RTS Cell Therapy Applications
Intrexon RTS® Cell Oncology: Immunotherapy Rare 13 Technology ©Therapy Disease: 2015 Based Empowering Rare Intrexon Expression Ocular Applications Skin RDEBCorp. Disease: CAR Broad Control All T Human Gene & Cartilage rights Disorders: GMand Utilizing reserved. Cell Cell Repair: Delivery Therapy Inf
Slide 14: Integrated Developments in Cell Therapies
Our©integrated January developments: March April Adoptive IMPROVED ATTSITE IMPLEMENTATION 14 2015 2015— 2015—strategic 2015—licensing TFULLY Intrexon Cell IMPROVED CRADA technology Therapies Therapy HUMAN Corp. TOWARD with collaboration agreement Approach All platforms IMPROVED the COMBI-CAR rights
Slide 15: Fibrocell Collaboration: RDEB Treatment
Cell-based Collaboration RDEB Plan Also 15 ©to pursuing 2015 is file a Treatments Intrexon debilitating an with IND Linear Fibrocell application Corp. scleroderma, for disease All Rare Science rights with Skinano the reserved. skin-hardening Diseases toapproved develop U.S. FDAgenetically-modified t
Slide 16: Gene-Based Therapeutics for Ocular Diseases with Sun Pharma
Gene-based Current Activator therapeutic Gene JV Use Initial 16 © with of2015 of target RTS® approaches Sun Interest Ligand Intrexon distribution Therapies is Pharma platform age-related GOIto Corp. developing chronic for with Ocular All macular activator rights ocular gene Diseases degeneration res
Slide 17: Health Field Pipeline
Health Field Oncology (ZIOPHARM, CAR/Cytokine •Adoptive Gastrointestinal Diseases (Intrexon Allergic Ocular (STALLERGENES) (Sun (Fibrocell) Rare Infertility (Agilis) Cartilage (OvaScience) (Histogenics) Malignant B-Cell Myeloid Solid Universal RTS-Controlled Skin Disease Pharma) / Collaborators Pipe
Slide 18: Developing API Production Using Biological Methods
Developing Traditional Chemical Isolation Intrexon’s Biological Inputs Engineering Design High Scalable Low UltraVector® Optimized Screening 18 © COGS yield productivity 2015 ofSpecification process of sugar, synthesis Approach production Process Intrexon Methods API Optimal biological DNA glycerol,
Slide 19: Bioengineering Methanotroph for Fuels and Chemicals
Bioengineering Organic Methane Fatty Intrexon Methanotroph We Through Given 19 ©developed 2015 acids low acids has bio-engineering CH3OH relative Intrexon Amino designed Growth is novel Methanotrophs anPyruvate acids input organism Corp. tools a proprietary cost we to All Isobutanol facilitate have
Slide 20: Trans Ova Genetics
Trans In With 20 the © Intrexon’s 2015 Ova Aprilis Genetics—Leading Intrexon 2014 a wholly technologies, TopCorp. Young ownedAllGenomic subsidiary Trans rights BovineOva reserved. Reproductive Bull of is positioned Intrexon List, 87%and Technologies of to the enable largest top unparalleled 100produ
Slide 21: AquaBounty AquAdvantage Salmon
AquaBounty AquAdvantage® seafood AAS Capture 1960 1980 Aquaculture 1990 2010 2030 2020 Supply Demand Source: 2050 21 © Demand Seafood and is 2015 1970 awaiting AquaBounty 1950 Gap Intrexon is 2000 Technologies—Majority is2040 aa $144 FDA pioneer Salmon Supply Corp. Technologies billion approval util
Slide 22: Okanagan Arctic Apple
Okanagan Arctic® additives OSF Small Conventional 22 © also is2015 quantities a Golden wholly developing Specialty Intrexon Arctic® and of owned Arctic® Corp. Fruits Arctic® beneficial Apple subsidiary All (OSF) apples Variety Granny rights traits of expected reserved. Apple in Intrexon apples peach
Slide 23: Exclusive Channel Collaboration Model
Scalable An applicability Exclusive Partner Strategic Commercialize Technology Intrexon 23 ©Exclusive 2015and Access License Intrexon Access of Capital Channel our Valuable toin All technology Fees Corp. Efficient a Collaboration Field ofCost Products Intrexon’s All rights recovery Model acrossreser
Slide 24: Increasing Capital Efficiency and Cost Recovery
Increasing Increase FY2012, 150% FY2012 Cost 60% 80% 0% 20% Revenues $40 *Q4 #the 24The Cash © second 2013 $30 40% Recovery 2015 agreement 100% operating $20 FY2013 Cost Q1 FY2013, (in Capital quarter Intrexon 50% 2014 $10 millions) Increase &with as $0 expenses FY2014 Deal % Q2 Efficiency FY2014 of
Slide 25: Financial Snapshot
Financial First Total EBITDA *106.1 ** #receptor agreement. 25Non-GAAP Includes Excludes © Quarter 2015 Cash million T-cell $(11.3) Snapshot 17,830,305 Intrexon and operating Fiscal financial (CAR-T) Investments million* Year Corp. shares expenses measure cancer 2015 All Basic (excluding of rights t
Slide 26: Driving Scale and Efficiency with BeyondBio Portal
Driving BeyondBio™ with 26 ©an 2015 integrated Scale Intrexon & portal Efficiency end-to-end Corp. will facilitate All Through capability rightsmore reserved. BeyondBio™ efficient collaboration Portal providing partners increased flexibility to tap into our knowledge base remotely and develop custom
Slide 27: Multiple Paths to Growing Royalties
Multiple Growing Royalties >25% 10-20% 0Mid-single Undisclosed Intrexon Joint S OvaXon Equity Company (NYSE) Subsidiary Subsidiaries Trans Wholly-owned 274&© 8IVenture Ventures 12 2015 Ophthalmic Ova Net Ownership Gross 8.7 Animal Value Paths Portfolio ECCs Symbol Profits Genetics Intrexon Industry
Slide 28: Intrexon Summary
Intrexon We for meaningful 28 © present apply 2015 Summary engineering Intrexon and returns future toCorp. our generations principles shareholders. All rights towhile artisanal reserved. delivering biological systems in large and established markets with built-in demand using a scalable capital effi
Slide 29: Appendix: Adjusted EBITDA Reconciliation
Appendix Intrexon Reconciliation Adjusted measure compensation, unrealized EBITDA decisions business Company’s investors, financial cash tool In definition amortization vary compensation expenses. securities control, to between obligations collaborators, in include and the useful 29 specific the add
Slide 30: Appendix: Net Income to Adjusted EBITDA Table
Appendix The 30 ©following 2015AIntrexon continued table presents Corp. Allarights reconciliation reserved.of net income attributable to Intrexon to EBITDA and also to Adjusted EBITDA, as well as the calculation of Adjusted EBITDA per share, for each of the periods indicated: